

Naveen L Pereira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9006679/publications.pdf>

Version: 2024-02-01

82
papers

2,545
citations

279798

23
h-index

214800

47
g-index

83
all docs

83
docs citations

83
times ranked

3871
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. <i>European Heart Journal</i> , 2022, 43, 959-967.	2.2	79
2	Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 322.	2.4	5
3	ABCDâ€“GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILORâ€“PCI Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024156.	3.7	22
4	Rare Genetic Variants Associated With Myocardial Fibrosis: Multi-Ethnic Study of Atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 804788.	2.4	6
5	Implementation of preemptive DNA sequenceâ€“based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. <i>Genetics in Medicine</i> , 2022, 24, 1062-1072.	2.4	28
6	Patient Onboarding and Engagement to Build a Digital Study After Enrollment in a Clinical Trial (TAILOR-PCI Digital Study): Intervention Study. <i>JMIR Formative Research</i> , 2022, 6, e34080.	1.4	2
7	Shotgun Immunoproteomics for Identification of Nonhuman Leukocyte Antigens Associated With Cellular Dysfunction in Heart Transplant Rejection. <i>Transplantation</i> , 2022, 106, 1376-1389.	1.0	4
8	Point of care CYP2C19 genotyping after percutaneous coronary intervention. <i>Pharmacogenomics Journal</i> , 2022, , .	2.0	0
9	Sexâ€“specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILORâ€“PCI Trial. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	1
10	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 549-559.	2.6	6
11	Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry. <i>American Heart Journal</i> , 2021, 232, 84-93.	2.7	10
12	Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. <i>Korean Circulation Journal</i> , 2021, 51, 797.	1.9	13
13	COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine. <i>Mayo Clinic Proceedings</i> , 2021, 96, 446-463.	3.0	62
14	The Role of Genetic Testing in the Evaluation of Dilated Cardiomyopathies. <i>Case Reports in Cardiology</i> , 2021, 2021, 1-4.	0.2	0
15	Heart-After-Liver Transplantation Attenuates Rejection of Cardiac Allografts in Sensitized Patients. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1331-1340.	2.8	18
16	Clinical Impact of Secondary Risk Factors in <i>TTN</i>-Mediated Dilated Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003240.	3.6	10
17	Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 739-750.	2.9	90
18	In replyâ€“COVID-19: Precision Medicine and Vascular Endothelium. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1672.	3.0	0

#	ARTICLE	IF	CITATIONS
19	Expanding Spectrum of Desmin-Related Myopathy, Long-term Follow-up, and Cardiac Transplantation. <i>Neurology</i> , 2021, 97, e1150-e1158.	1.1	4
20	Reply. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1501.	2.9	0
21	Rapid Exclusion of COVID Infection With the Artificial Intelligence Electrocardiogram. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2081-2094.	3.0	15
22	Rare TBX4 Variant Causing Pulmonary Arterial Hypertension With Small Patella Syndrome in an Adult Man. <i>JACC: Case Reports</i> , 2021, 3, 1447-1452.	0.6	3
23	Artificial Intelligence-Enabled Electrocardiography to Screen Patients with Dilated Cardiomyopathy. <i>American Journal of Cardiology</i> , 2021, 155, 121-127.	1.6	15
24	Genotype-Guided P2Y ₁₂ Inhibitor Therapy After Percutaneous Coronary Intervention: A Bayesian Analysis. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, CIRCGEN121003353.	3.6	6
25	Genetics of dilated cardiomyopathy: practical implications for heart failure management. <i>Nature Reviews Cardiology</i> , 2020, 17, 286-297.	13.7	133
26	Circulating Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 70-80.	4.1	21
27	Effect of Genotype-Guided Oral P2Y ₁₂ Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 761.	7.4	257
28	Soluble Natriuretic Peptides in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e012943.	3.7	15
29	Updates on the Genetic Paradigm in Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 37.	0.9	1
30	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y ₁₂ Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	2.9	366
31	Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, 458-485.	3.6	39
32	Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2676-2688.	2.8	38
33	Prognostic Biomarkers for Precision Medicine in Heart Transplant: Is Galectin-3 the One?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 889-891.	0.6	0
34	Predictors and Outcomes of Renal Replacement Therapy After Left Ventricular Assist Device Implantation. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1003-1014.	3.0	13
35	Clopidogrel Pharmacogenetics. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007811.	3.9	139
36	Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas ã cause du BNP?. <i>European Journal of Heart Failure</i> , 2019, 21, 609-612.	7.1	3

#	ARTICLE	IF	CITATIONS
37	International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing. <i>Pharmacogenetics and Genomics</i> , 2019, 29, 76-83.	1.5	13
38	Nonhuman leukocyte antigen antibodies that have impact in the heart transplant patient. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 279-285.	1.6	5
39	Galectina-3 como biomarcador en el trasplante cardiaco: ¿hacia la medicina de precisión?. <i>Revista Espanola De Cardiología</i> , 2019, 72, 889-891.	1.2	1
40	Spectrum of Restrictive and Infiltrative Cardiomyopathies. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1130-1148.	2.8	91
41	Spectrum of Restrictive and Infiltrative Cardiomyopathies. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1149-1166.	2.8	48
42	Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients. <i>Journal of the American College of Cardiology</i> , 2018, 71, 636-650.	2.8	81
43	Small bowel bleeding in patients with left ventricular assist device: outcomes of conservative therapy versus balloon-assisted enteroscopy. <i>Annals of Gastroenterology</i> , 2018, 31, 692-697.	0.6	2
44	Response by Wong et al to Letter Regarding Article, "Importance of Routine Antihuman/Leukocyte Antibody Monitoring: De Novo Donor Specific Antibodies Are Associated With Rejection and Allograft Vasculopathy After Heart Transplantation". <i>Circulation</i> , 2018, 137, 1872-1873.	1.6	0
45	Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1372-1380.	0.6	11
46	Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. <i>Journal of Personalized Medicine</i> , 2018, 8, 8.	2.5	65
47	Genomewide association study reveals novel genetic loci associated with change in renal function in heart transplant recipients. <i>Clinical Transplantation</i> , 2018, 32, e13395.	1.6	8
48	International Analysis of LVAD Point-of-Care Versus Plasma INR: A Multicenter Study. <i>ASAIO Journal</i> , 2018, 64, e161-e165.	1.6	7
49	Elevated $\text{ST} > 2$ levels are associated with antibody-mediated rejection in heart transplant recipients. <i>Clinical Transplantation</i> , 2018, 32, e13349.	1.6	12
50	Unraveling the Puzzle of the Role of Heritability in the Variability of the QT Interval Using Exome Array Analysis. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002007.	3.6	0
51	Sirolimus Therapy Is Associated with Elevation in Circulating PCSK9 Levels in Cardiac Transplant Patients. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 9-15.	2.4	18
52	Personalizing Antiplatelet Therapies for Acute Coronary Syndrome (ACS) in Patients Undergoing Percutaneous Coronary Intervention (PCI): Are They Cost-effective?. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 1-3.	2.6	0
53	Time to achieving therapeutic international normalized ratio increases hospital length of stay after heart valve replacement surgery. <i>American Heart Journal</i> , 2017, 187, 70-77.	2.7	8
54	Importance of Routine Antihuman/Leukocyte Antibody Monitoring. <i>Circulation</i> , 2017, 136, 1350-1352.	1.6	12

#	ARTICLE	IF	CITATIONS
55	Previously Unreported in Women <i>Galactosidase Alpha</i> Pro409Ser Variant Is Associated With Fabry Disease. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, e001661.	5.1	4
56	Kidney transplantation as a therapeutic option for end-stage renal disease developing after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 297-304.	0.6	23
57	Genetic Risk and Altering Lipids With Lifestyle Changes and Metformin. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 469-471.	5.1	0
58	Pharmacogenetics of Clopidogrel. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 185-188.	5.1	15
59	Circulating Galectin-3 Levels Are Persistently Elevated After Heart Transplantation and Are Associated With Renal Dysfunction. <i>JACC: Heart Failure</i> , 2016, 4, 847-856.	4.1	23
60	Sex Related Differences in the Risk of Antibody-Mediated Rejection and Subsequent Allograft Vasculopathy Post-Heart Transplantation: A Single-Center Experience. <i>Transplantation Direct</i> , 2016, 2, e106.	1.6	19
61	Proximal thoracic aorta dimensions after continuous-flow left ventricular assist device implantation: Longitudinal changes and relation to aortic valve insufficiency. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 423-432.	0.6	27
62	Developing EHR-driven heart failure risk prediction models using CPXR(Log) with the probabilistic loss function. <i>Journal of Biomedical Informatics</i> , 2016, 60, 260-269.	4.3	64
63	Preoperative Determinants of Quality of Life and Functional Capacity Response to Left Ventricular Assist Device Therapy. <i>Journal of Cardiac Failure</i> , 2016, 22, 797-805.	1.7	33
64	Circulating Atrial Natriuretic Peptide Genetic Association Study Identifies a Novel Gene Cluster Associated With Stroke in Whites. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 141-149.	5.1	17
65	Clinical Implementation of Cardiovascular Pharmacogenomics. <i>Mayo Clinic Proceedings</i> , 2015, 90, 701-704.	3.0	8
66	Genotype-based clinical trials in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2015, 12, 475-487.	13.7	37
67	A Functional Genetic Variant (N521D) in Natriuretic Peptide Receptor 3 Is Associated with Diastolic Dysfunction: The Prevalence of Asymptomatic Ventricular Dysfunction Study. <i>PLoS ONE</i> , 2014, 9, e85708.	2.5	9
68	The Role of Donor-Specific Antibodies in Acute Cardiac Allograft Dysfunction in the Absence of Cellular Rejection. <i>Transplantation</i> , 2014, 98, 229-238.	1.0	12
69	The Role of Medical Management for Acute Intravascular Hemolysis in Patients Supported on Axial Flow LVAD. <i>ASAIO Journal</i> , 2014, 60, 9-14.	1.6	32
70	Contemporary Strategies in the Diagnosis and Management of Heart Failure. <i>Mayo Clinic Proceedings</i> , 2014, 89, 662-676.	3.0	24
71	Advanced Cardiac Amyloidosis Associated with Normal Interventricular Septal Thickness: An Uncommon Presentation of Infiltrative Cardiomyopathy. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 440-447.	2.8	30
72	Changes in Cardiopulmonary Exercise Testing Parameters Following Continuous Flow Left Ventricular Assist Device Implantation and Heart Transplantation. <i>Journal of Cardiac Failure</i> , 2014, 20, 548-554.	1.7	65

#	ARTICLE	IF	CITATIONS
73	Relationship between monoclonal gammopathy and cardiac amyloid type. <i>Cardiovascular Pathology</i> , 2013, 22, 189-194.	1.6	52
74	TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 658-665.	1.5	17
75	Natriuretic Peptide Receptor-3 Gene (NPR3). <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 201-210.	5.1	12
76	Donor-Specific Antibodies to Class II Antigens Are Associated With Accelerated Cardiac Allograft Vasculopathy. <i>Transplantation</i> , 2013, 95, 389-396.	1.0	65
77	Cardiac allograft hypertrophy is associated with impaired exercise tolerance after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1153-1160.	0.6	12
78	De Novo Development of Eosinophilic Myocarditis With Left Ventricular Assist Device Support as Bridge to Transplant. <i>Annals of Thoracic Surgery</i> , 2010, 90, 1345-1347.	1.3	5
79	Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices†. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2010, 11, 503-505.	1.1	48
80	Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices: a time for reappraisal. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2010, 11, 505-506.	1.1	1
81	Natriuretic peptide pharmacogenetics: Membrane metallo-endopeptidase (MME): Common gene sequence variation, functional characterization and degradation. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 864-874.	1.9	24
82	Cardiovascular pharmacogenomics and individualized drug therapy. <i>Nature Reviews Cardiology</i> , 2009, 6, 632-638.	13.7	61